Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300

Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $285 to $300.